Updated: Thursday 24 November 2022
- We recommend that people with kidney disease get their Covid-19 vaccination autumn boosters. Even for people with weakened immune systems, repeated vaccinations can gradually improve and maintain your level of antibodies and enhance the other parts of your immune system that respond to Covid-19 infection.
- Evusheld will now be made available privately (not via the NHS). For more information please see our FAQs on Evusheld page.
- As with all viruses, the Covid-19 virus has changed over time. This can affect how well Covid-19 medicines work. Some recent data suggests that the drug Evusheld may be less protective against some of the new variants. We will publish more information as soon as we have it, but it is important to take into account new information if you are considering purchasing the drug.
- We are extremely disappointed that Evusheld is still not available despite being approved by the MHRA in March 2022, when earlier variants were circulating. We will continue to campaign for effective protection against Covid-19 for people who are immunosuppressed
- A new study will test the level of immune protection that Evusheld offers to vulnerable patients, and whether this protection can be improved by a repeat Covid-19 vaccination. It is open to recruitment at Oxford University Hospitals NHS Foundation Trust, The Royal Marsden Hospital, and Northampton General Hospital. See the study website for more information.
- NICE (National Institute for Health and Clinical Excellence) have issued draft guidance for consultation which recommends that only three out of the eight treatments they have reviewed are available on the NHS. This is draft guidance and therefore it will not affect which drug treatments people are currently offered should they test positive for Covid-19. See our news story.